Mainz Biomed

Mid-Year Update from Mainz Biomed Mainz Biomed (NASDAQ: MYNZ) has released its financial results for the first half of 2024, along with key corporate updates and strategic plans for 2025: Financial Progress: ▪️ Our revenue climbed by 4% year-over-year, while we streamlined operations while loss from operations decreases by 32%. Major Scientific Achievements: ▪️ We unveiled groundbreaking data from our eAArly DETECT study at Digestive Disease Week (DDW) 2024, leading results: 97% sensitivity for colorectal cancer (CRC) and 82% for advanced precancerous lesions. ▪️ Additionally, we enhanced our flagship ColoAlert® product, introducing key improvements that deliver faster, more accurate results, setting new standards in screening efficiency. Our vision for the future is crystal clear: ▪️Expanding ColoAlert® across Europe. ▪️Developing a next-generation colorectal cancer screening solution. ▪️Running a 2,000 patient study, with average risk patients in the U.S., to read out in the second half of 2025. With eAArly DETECT 2, the Company addresses the recent FDA feedback and prepares for a new submission for breakthrough device designation with an expanded data set. Read the full press release: https://lnkd.in/dQ9g28NC With these strategic priorities in place, Mainz Biomed is poised for a strong close to 2024 and an even more impactful year ahead! $MYNZ #StockMarketNews #Nasdaq #Biotech #Growth #ColonCancer #Earlydetection

Surge in Demand for Enhanced ColoAlert: A New Era in Colorectal Cancer Screening In the fight against colorectal cancer, early detection is critical. At Mainz Biomed N.V., we’re experiencing a surge in demand for our enhanced ColoAlert test, launched in July 2024. This growing interest from laboratory partners underscores the increasing importance of innovative screening tools, helping healthcare providers offer faster, more accurate results to patients who need it most. Key Drivers Behind the Demand: ▪️ Optimized Screening Efficiency: The enhanced ColoAlert streamlines the process, delivering more reliable results while improving lab efficiency. ▪️ Improved User Experience: Innovations like our proprietary DNA stabilizing buffer and simplified at-home collection devices minimize retesting and ensure patients receive results within 2–3 days. ▪️Trusted Partnerships: Leading labs like GANZIMMUN Diagnostics are embracing the enhanced ColoAlert, recognizing the value of faster turnaround times and more effective screening for their patients. 📅 GANZIMMUN will showcase these innovations at the 57th Medizinische Woche Baden-Baden from October 30 to November 3, 2024, as we strive to make early detection the standard in cancer care. Learn more: https://lnkd.in/dKsJuXKm $MYNZ #Biotech #ColonCancer #EarlyDetection #HealthCare #Innovation

At Mainz Biomed (NASDAQ: MYNZ), we are dedicated to delivering on key milestones. Our strong clinical results and expanding pipeline highlight our potential; however, management believes the Company’s current stock price does not adequately reflect its true value. While we cannot directly influence the stock market, our management team is fully focused on executing our strategy to unlock value for shareholders. A cornerstone of our approach is transparency. We are committed to keeping our investors informed about our progress and strategic initiatives. In line with Nasdaq and SEC rules, we plan to file our June 30, 2024, financials this month, ensuring timely communication with our stakeholders. As we prepare for FDA clinical trials in 2025, we recognize this as a critical opportunity for growth. Successfully navigating the regulatory landscape in the U.S. will unlock significant opportunities to serve millions of patients in the world’s largest healthcare market. In line with this strategy, we plan to expand our dataset to include a larger average-risk patient population and plan to submit comprehensive data to the FDA in 2025. The consistently positive data from our clinical feasibility studies, presented at ASCO 2024 and Digestive Disease Week (DDW), provide a strong foundation as we prepare for U.S. FDA clinical trials. Successful completion of a pivotal will allow Mainz Biomed’s next-generation CRC screening test to be marketed to millions of Americans at risk of colorectal cancer, representing a major revenue growth opportunity for the company. As we forge ahead, our unwavering dedication to advancing early cancer screening can position us to make a meaningful impact on public health. We remain committed to maximizing shareholder value while enhancing patient outcomes through groundbreaking innovations in cancer detection. Read the full Press Release: https://lnkd.in/dUu4gYWm $MYNZ #Nasdaq #StockMarketNews #Biotech #ColonCancer #Biotech #Science #Research

Following encouraging feedback from the FDA, we’ve made the strategic decision to withdraw our breakthrough device designation application to focus on expanding our clinical research program to address feedback received from the FDA. We will expand our patient dataset to include a larger average-risk patient population. We plan to submit this comprehensive data in 2025 to FDA. Exciting progress ahead for Mainz Biomed! #MYNZ #NASDAQ #Biotech #Innovation #FDA

Petra Smeltzer Starke Joins Mainz Biomed to Lead the Charge in Early Detection of Colon Cancer! We’re thrilled to welcome Petra Smeltzer Starke to the Mainz Biomed team! With her incredible experience—from advising in the White House to working with global leaders—Petra will help us raise awareness about one of the most critical health priorities: early detection of colon cancer. Catching colon cancer early can make all the difference. Our innovative screening tools aim to find the disease in its earliest stages when it’s most treatable. With Petra on our side, we’re working to make sure more people know how vital early detection is for saving lives. More information: https://lnkd.in/daGKP98X #MainzBiomed #ColonCancerAwareness #EarlyDetectionMatters #PetraSmeltzerStarke #CancerScreening

Our collaboration with Liquid Biosciences highlights our dedication to addressing pancreatic cancer, a disease responsible for approximately 466,000 deaths annually and with a global five-year survival rate of just around 11%. Utilizing advanced AI technology, we are advancing early detection with PancAlert. Supported by the German Federal Ministry of Education and Research, our initial results are promising.   We are now expanding our biomarker research and AI development, with a goal to complete this phase by Q4 2024. Together with Liquid Biosciences, we are making significant strides in the detection of this challenging cancer. Learn more: https://lnkd.in/dHzUcu_w   $MYNZ #PancreaticCancer #Healthcare #BePartOfTheChange #Innovation #biotech #stockmarketnews #stockmarkettoday #investing

Mainz Biomed is pleased to announce significant improvements to its ColoAlert product. The enhancements include a new DNA stabilizing buffer to handle varying sample volumes, reducing the need for retests and ensuring quicker results. Additionally, the kit's improved usability features, including an enhanced collection device and a new tube holder, make the sample collection process easier and more user-friendly. The updated ColoAlert product is now accessible to the existing laboratory partners and prospective collaborators. #crcscreening #earlydetection  Learn more: https://lnkd.in/dkiM5MsY    If you would like to be kept up to date with the very latest news, please subscribe to our newsletter: https://lnkd.in/dXSwQd4h  NASDAQ: $MYNZ

Mainz Biomed is pleased to announce significant improvements to its ColoAlert product. The enhancements include a new DNA stabilizing buffer to handle varying sample volumes, reducing the need for retests and ensuring quicker results. Additionally, the kit's improved usability features, including an enhanced collection device and a new tube holder, make the sample collection process easier and more user-friendly. The updated ColoAlert product is now accessible to the existing laboratory partners and prospective collaborators. #crcscreening #earlydetection  Learn more: [Link to PR]    If you would like to be kept up to date with the very latest news, please subscribe to our newsletter: https://lnkd.in/dXSwQd4h  NASDAQ: $MYNZ

Mainz Biomed has submitted its Next Generation CRC screening test for FDA Breakthrough Device Designation, backed by consistently excellent clinical data. With clinical results showcasing a 97% sensitivity for colorectal cancer and 88% for advanced adenomas, promises significant advancements in early cancer detection. This designation aims to expedite the review and approval process of the next gen CRC screening test. #fda #nextgencrcscreening Learn more: https://lnkd.in/dxvZrsiP If you would like to be kept up to date with the very latest news, please subscribe to our newsletter: https://lnkd.in/dXSwQd4h

Mainz Biomed reviews major H1 2024 achievements and provides a corporate update, including the prestigious DDW Poster of Distinction Award for industry-leading results.#Biotech #CancerDetection Read more: https://lnkd.in/dMD79igi If you would like to be kept up to date with the very latest news, please subscribe to our newsletter: https://lnkd.in/dXSwQd4h NASDAQ: $MYNZ